Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | AGXT | P21549 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | LPO | P22079 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195503 | 0.87 | SMN1; SMN2 (0.60) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL5315445 | 0.83 | TAAR1 (0.67) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL1145614 | 0.83 | TAAR1 (0.60) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL30080050 | 0.82 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL2099512 | 0.82 | CHRM2 (0.66) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL723511 | 0.82 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL3156159 | 0.80 | IDO1 (0.62) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL7323232 | 0.80 | MAOB (0.43) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL3689085 | 0.80 | CHRM2 (0.63) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL29908907 | 0.80 | TAAR1 (0.62) | TAAR1IDO1AGXTCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207253-A1 | Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-06-27 | — | — | US | claimed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | claimed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134016-A | Tricyclic heterocycles | 默克专利股份公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4146652-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | Merck Patent GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-115515959-A | Tricyclic heterocycles as TEAD binders | 默克专利股份公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2022245951-A1 | INHIBITORS OF CDR1 FOR REVERSAL OF AZOLE DRUG RESISTANCE IN FUNGAL INFECTIONS | UNM RAINFOREST INNOVATIONS (US) | 2022-11-24 | — | — | WO | claimed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
| US-5677324-A | MUSCLE RELAXANTS | PFIZER INC. (US) | 1997-10-14 | — | — | US | claimed |
| EP-0634998-B1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | claimed |
| EP-0690855-B1 | BENZOPYRANES AS POTASSIUM CHANNEL OPENERS | PFIZER LTD (GB) | 1996-12-18 | — | — | EP | claimed |
| CN-1119014-A | Benzopyranes as potassium channel openers | PFIZER LTD (GB) | 1996-03-20 | — | — | CN | claimed |
| EP-0690855-A1 | BENZOPYRANES AS POTASSIUM CHANNEL OPENERS | PFIZER LTD (GB) | 1996-01-10 | — | — | EP | claimed |
| WO-1994020491-A1 | BENZOPYRANES AS POTASSIUM CHANNEL OPENERS | PFIZER LIMITED (GB) | 1994-09-15 | — | — | WO | claimed |
| EP-0300865-B1 | DERIVATIVES OF N-AMINOBUTYL-N-PHENYL ARYL AMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SYNTHELABO (FR) | 1992-03-18 | — | — | EP | claimed |
| EP-0251194-A1 | Use of carbocyclic and heterocyclic condensed dihydropyridines for the preparation of cardioprotective remedies and heterocyclic and carbocyclic condensed dihydropyridines and methods and intermediates for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1988-01-07 | — | — | EP | claimed |
| US-4102929-A | Asymmetric synthesis of organic compounds | HOFFMANN-LA ROCHE INC. (US) | 1978-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | TAAR1 3949/4885IDO1 3982/4885AGXT 3334/4885 |
| US-20240207253-A1 | Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections | ABCC1, ABCC2, ERG28 | TAAR1 3116/4885IDO1 1065/4885AGXT 2488/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | TAAR1 3665/4885IDO1 3847/4885AGXT 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.